Research in contextEvidence before this studyWe searched PubMed for the articles published up to October 2018 using the terms "non-small cell lung cancer (NSCLC)", "epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)", "predictive factor", and "co-occurring mutation". We found that a few studies have investigated the associations between co-occurring somatic gene mutations and EGFR-TKI efficacy, with inconsistent results. Some studies indicated that concomitant somatic mutations were negative predictive factors of EGFR-TKI therapy, while the other studies indicated that the tumor-suppressor genes and oncogenes rather than the number of mutations were associated with poorer efficacy of EGFR-TKI. However, these relations have not been demonstrated in real world datasets.Added value of this studyIn this study, we collected two groups of *EGFR* positive patients with comparable clinical characteristics and different progression-free survival spans who were treated with first generation EGFR-TKIs. To the best of our knowledge, it is the first real-world cohort to demonstrate the relationship between co-occurring somatic gene mutations and EGFR-TKI efficacy. We investigated genetic discrepancy using next generation sequencing. We also compared the differences in mutation number, oncogenes, and tumor mutation burden between the two groups.Implications of all the available evidenceSignificantly more co-occurring oncogene mutations and higher T790 M to *EGFR* mutation abundance ratio were found in patients in the short PFS group. Our data confirmed the impact of co-occurring oncogenes in EGFR-TKI treatment. Thus, multiple oncogene mutations besides *EGFR* mutations could be tested prospectively to provide better predictions of EGFR-TKI efficacy and disease progression.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Tyrosine kinase inhibitors (TKIs) are clinically effective in non-small cell lung cancer (NSCLC) patients who have epidermal growth factor receptor (*EGFR*) oncogene mutations \[[@bb0005]\]. Among the variety of *EGFR* oncogenic mutations, in-frame microdeletions around the Leu-Arg-Glu-Ala (LREA) residues of exon 19, and the L858R substitution in exon 21 of *EGFR* comprise approximately 90% of all *EGFR* mutations detected in advanced NSCLC patients. The aforementioned mutations were described as sensitizing *EGFR* mutations and were reported to be predictive markers of tumor responses to EGFR-TKIs. During the last two decades, randomized trials have demonstrated a median progression-free survival (PFS) of 9·3--14·4 months in patients harbouring sensitizing *EGFR* mutations treated with first-generation EGFR-TKIs \[[@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]\]. Despite the high efficacy of TKIs, some patients with EGFR-mutant lung cancer acquire resistance to the drug in \<6 months, while others\' PFS are longer than 24 months. As such, there may be factors other than *EGFR* mutations that contribute to disease progression. Although previous studies have investigated the association of concomitant genetic alterations with response and survival \[[@bb0035], [@bb0040], [@bb0045], [@bb0050]\], the results are conflicting.

We hypothesized that other molecular markers could contribute to the prediction of EGFR-TKI efficacy. To explore this hypothesis, we retrospectively screened our centre\'s patient database and performed next generation sequencing (NGS) of archival tissue from EGFR-mutant lung cancers patients. To better identify the differences between groups, we only selected patients with long or short PFS.

2. Materials and methods {#s0025}
========================

2.1. Patient enrolment {#s0030}
----------------------

A total of 423 consecutive patients with advanced NSCLC (stage IIIB or IV) possessing 19del or 21L858R *EGFR* mutations who had received first generation EGFR-TKI therapy (gefitinib, erlotinib, or icotinib) at Peking Union Medical College Hospital between 2013 and 2018 were screened. Of these, 71 patients were included in the study.

All patients had been pathologically diagnosed with NSCLC. *EGFR* mutations were detected using an amplification refractory mutation system (ARMS). Patients were followed up regularly. Computed tomography (CT) of the thorax and abdomen were performed one month after the initiation of TKIs and every two months subsequently. Magnetic Resonance Imaging (MRI) was performed at baseline and every two months in patients with central nervous system (CNS) metastasis. Patients with symptomatic CNS metastasis or leptomeningeal metastasis were not included in the study. Objective response and progression of disease was assessed according to the response evaluation criteria in solid tumours (RECIST) 1·1 criteria \[[@bb0055]\]. Patients with PFS longer than 24 months or shorter than six months were included and stratified into two groups. PFS was calculated based on the start of EGFR-TKI therapy to disease progression or death. Overall survival (OS) was calculated from the start of EGFR-TKI therapy to death.

Demographic characters were reviewed based on patients\' clinic record files. Age, sex, smoking status, clinical stage, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and TKI treatment were included in analysis.

This study was approved by the Peking Union Medical College Hospital review board. Informed consent was obtained from all patients for use of tissue in genetic analysis. Pre-TKI treatment tumor tissue were collected and evaluated for NGS. Matched blood samples were collected as normal controls ([Fig. 1](#f0005){ref-type="fig"}). Genetic test using a panel of 416 cancer-related genes (Supplementary Table 1) were performed at Nanjing Shihe Jiyin Biotechnology Inc. (Jiangsu, China).Fig. 1Flowchart of the study design.NSCLC = non-small cell lung cancer. PFS = progression-free survival. EGFR = epidermal growth factor receptor. TKI = Tyrosine kinase inhibitors. NGS = next-generation sequencing.Fig. 1

3. Sequence analysis {#s0035}
====================

3.1. Sample preparation {#s0040}
-----------------------

Tissue blocks with adequate tumor cellularity were selected by the pathologists who made the diagnosis. Formalin-fixed paraffin-embedded (FFPE) tissues from 10 to 15 unstained slides of 5-μm thick sections were prepared using PCR precautions. DNA was isolated and purified using the QIAamp DNA FFPE Kit (QIAGEN). Quantity of DNA was measured usingQubit 3·0 with a dsDNA HS Assay Kit (Life Technologies).

3.2. Library preparation and sequencing {#s0045}
---------------------------------------

Sequencing libraries were prepared using the KAPA Hyper Prep kit (KAPA Biosystems) with an optimised manufacturer\'s protocol. In brief, 1 μg of genomic DNA was sheared into fragments using the Covaris M220 instrument (Covaris), and then subjected to end-repairing, A-tailing, and ligation with indexed adapters sequentially, followed by size selection using Agencourt AMPure XP beads (Beckman Coulter). Finally, libraries were amplified by PCR and purified for target enrichment.

For target enrichment, indexed DNA libraries were pooled together for hybridization with customized biotinylated-DNA probes (GeneseeqOne, Nanjing Geneseeq Technology Inc.) targeting 416 cancer-relevant genes (exons and selected introns for fusion detection).

Enriched libraries were amplified and subjected for NGS on Illumina Hiseq4000 NGS platforms (Illumina) according to manufacturer\'s instructions. For blood samples, sequencing depth was at least 100× mean coverage by non-PCR duplicate read pairs. For tumor specimens, sequencing depth was 500× mean coverage by non-PCR duplicate read pairs.

3.3. Data processing {#s0050}
--------------------

Trimmomatic was used for FASTQ file quality control (QC) \[[@bb0060]\]. Sequencingreads were mapped to the reference sequence Human Genome (hg19) using a Burrows-Wheeler Aligner (BWA-mem, v 0·7·12) \[[@bb0065]\]. Local realignment around indels and base quality score recalibration were applied using the Genome Analysis Toolkit (GATK 3·4·0) \[[@bb0070]\]. VarScan2 was employed for detection of somatic mutations \[[@bb0075]\]. We required VAF ≥2% (≥ 8 variant supporting reads) with somatic *p*-value = 0·1, minimum quality score = 20 and variant supporting reads mapped to both strands with strand bias no \>10%. The mutation list was further filtered through an internally collected list (\~2000 normal samples) of recurrent artifacts on the same sequencing platform. Mutations were also removed if they were present in \>1% population frequency in the 1000 Genomes Project or 65,000 exomes project (ExAC). Annotation of mutations was performed using ANNOVAR \[[@bb0080]\]. Copy number variations (CNVs) were detected using ADTEx with default parameters. Genomic fusions were identified by FACTERAwith default parameters \[[@bb0085]\].

TMB was defined as the number of somatic, coding, base substitution, and indel mutations per megabase of genome examined. For our panel TMB calculation, all non-synonymous alterations and indels in the coding region of targeted genes were considered with the exception of known hotspot mutations in oncogenic drivers and truncations in tumor suppressors. The validation of TMB calculation using our panel is shown in Supplementary Fig. 1.

3.4. Statistical analysis {#s0055}
-------------------------

The Wilcoxon rank-sum test or χ^2^ test and Fisher\'s exact test was used to test differences in clinical and genetic parameters between patients with different PFS. Non-parametric tests were used to compare mutation number between groups. Survival curves were estimated using the Kaplan-Meier method. The statistical significance level was defined as two-sided *P* \< 0·05. SPSS statistical software, version 19·0 (IBM Corp., Armonk, NY, USA) was used to perform statistical analysis. Forset plot was drawn by GraphPad Prism, version 8·0·2.

4. Results {#s0060}
==========

4.1. Patient characteristics {#s0065}
----------------------------

Of the 71patients, 41 belonged to the long PFS group and 30 belonged to the short PFS group.The median PFS and OS in the two groups of patients were 36·3 months (95% CI 32·0--40·6) vs. 3·9 (95% CI 3·0--4·8) months, and 63·6 months (95% CI 57·4--69·8) vs. 19·4 months (95% CI 8·6--31·2) (Supplementary Fig. 2A and 2B). The median age of all the patients was 60 years(range, 36-78 years). The distributation of age, gender, smoking status, ECOG score, tumor stage, mutation types, and lines of TKIs were not significantly different between the two groups. Patients\' clinical characteristics and *EGFR* mutations detected using ARMS sequencing are given in [Table 1](#t0005){ref-type="table"}.Table 1Baseline characteristics of patients in long and short PFS groups.Table 1CharacteristicNo. of patientsLong PFS groupShort PFS group*P* value714130Age\>65 years231670·127Gender0·125 Male231013 Female483117Smoking status0·780 Never smoker543222 Ever smoker1798ECOG score0·304 0--1674027 ≥2413Clinical stage0·069 IIIb550 IV663630EGFR mutations1·000 19del281612 21L858R432518TKI lines1·000 1st line593425 ≥2nd line1275TKI treatments0·638 Gefitinib532924 Erlotinib1394 Icotinib532

4.2. Mutations detected by NGS in all patients {#s0070}
----------------------------------------------

Sensitive *EGFR* mutations of 19del or 21L858R were detected in all 71 patients. The *EGFR* mutation types detected by NGS were consistent with the result obtained through ARMS PCR, with the exception of two patients with co-occurring 19del and 21L858R mutations. The 21L858R mutation was the major *EGFR* mutation type in both groups (61% in the short PFS group vs. 60% in the long PFS group). The 19del mutations consisted of several different types. The most frequent 19del mutation type was del745/746-750 (41% in the short PFS group vs. 43% in the long PFS group), followed by del746insA, del747insS, S752fs, A750fs, and T751P. Complex *EGFR* mutations were found in 22 patients (31%), including 12 patients with complex exon20 T790M mutation and four patients with more than one EGFR-sensitive mutation of exons 19 or 21. The remaining five patients had co-occurring *EGFR* mutations of exon28 1142-1155del, exon20 R776H, exon18 E709K, exon18T710N, and exon18 L718 M. *EGFR* amplification was found in 18% patients. In the long PFS group, the most frequent accompanying somatic mutations were *TP53* (51%), followed by *MAP2K2* (15%), *NKX2-1* (15%), *CTNNB1* (15%), and *RB1* (12%). In the short PFS group, the most frequent accompanying somatic mutations were *TP53* (63%), followed by *RB1* (17%), *FAT1* (17%), and *ABCB1* (13%) (Supplementary Fig. 3). We further did cluster analysis and gene ontology (GO) analysis of the 71 patients. The results were shown in Supplementary Fig. 4 and Supplementary Fig. 5.

4.3. Differences in mutations between two groups {#s0075}
------------------------------------------------

The percentage of 21L858R and 19del mutations were not significantly different between the two groups (*P* = 1·000). Patients in the long PFS group tended to have more exon19 deletion mutations of del745/746-750 (82% vs. 54% in the short PFS group, *P* = 0·121), fewer T790M mutations (10% vs. 27% in the short PFS group, *P* = 0·106), and fewer complex *EGFR* mutations (22% vs. 43% in the short PFS group; *P* = 0·071), but the differences were not statistically significant ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Gene mutations in pretreated FFPE samples of patients in the two groups.Fig. 2

We further analysed T790M abundance in T790M-positive samples. Mean T790M frequency was 0·77% in the long PFS group and 9·15% in the short PFS group (*P* = 0·053). To minimise the impact of different proportions of cancer cells and genetic heterogeneity in each sample, we also compared the ratio of T790M alleles to *EGFR* sensitive mutation alleles. The result indicated that patients in the long PFS group had a relatively lower ratio (mean of 8·09% vs. 109·22% in the short PFS group; *P* = 0·037) (Supplementary Table 2).

TP53 mutations were the most frequent mutation in both groups, and the missense mutation occurred more often in the short PFS group (27% vs. 47% in the short PFS group, *P* = 0·131). The *PIK3CA* missense mutation was seen only in the short PFS group (*P* = 0·071), while the MAP2K2 mutations were seen only in the long PFS group (*P* = 0·036).

Co-occurring driver mutations \[[@bb0090]\] other than *EGFR* mutations were detected only in the short PFS group. Among them, one patient had *ALK* fusion gene, one patient had *MET* amplification,and one patient had *BRAF V600E*. Accompanying driver oncogene mutations were significantly prevalent in the short PFS group (10% vs. 33% in the short PFS group, *P* = 0·018).

Other genetic variants that might be associated with PFS were also analysed, including *RB1*, *PIK3CA*, *EGFR* amplification and *BIM* polymorphism, but no statistically significant differences could be found. The number of co-occurring somatic mutations detected by NGS were 7·63 ± 0·50 and 8·43 ± 0·65 (*P* = 0·314) in the long and short PFS groups, respectively. Among the somatic mutations, the mean number of EGFR pathway-related mutations were 1·51 ± 0·19 vs. 1·37 ± 0·18 (*P* = 0·652) in the two groups ([Table 2](#t0010){ref-type="table"}).Table 2Differences in genetic alterations between two groups detected using NGS.Table 2Long PFS groupShort PFS groupPNo.Percent (%)No.Percent (%)21L858R2561%1860%1·00019 Del1741%1343%1·000Del746--7501482%754%0·121Complex EGFR mutations922%1343%0·071T790M mutation410%827%0·106Co-occurring driver gene mutation410%1033%0·018Number of mutations7.63 ± 0.508·43 ± 0·650·314EGFR pathway related mutations1.51 ± 0.191·37 ± 0·180·652Non EGFR pathway mutations4.83 ± 0.415·57 ± 0·590·337TP 53 mutations2254%2067%0·332TP53 missense mutation1127%1447%0·131RB1 mutations512%516%0·733PIK3CA missense mutation0--310%0·071MAP2K2615%0--0·036EGFR amplification615%723%0·371BIM polymorphism410%413%0·714

The relationship between genetic heterogeneity and PFS were further analysed. In multivariate analysis, co-occurring driver mutations and *MAP2K2* were independent predictive factors (Supplementary Fig. 6).

4.4. Tumor mutation burden (TMB) analysis {#s0080}
-----------------------------------------

TMB for each patient was calculated. The mean TMB was 7·3 ± 5·2 mutations/Mb in the 71 patients. Mean TMBs for the two groups were 6·7 ± 0·7 for the long PFS group vs. 8·2 ± 1·0 for the short PFS group (*P* = 0·172). Patients with TMBs higher than eight mutations/Mb tended to fall into the short PFS group, where 29·3% of patients in the long PFS group vs. 50·0% of patients in the short PFS group had TMBs higher than eight mutations/Mb (*P* = 0·056) but the difference was not significant([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Distribution of tumor mutation burden in the 71 patients.TMB = tumor mutation burden. PFS = progression-free survival.Fig. 3

5. Discussion {#s0085}
=============

*EGFR* mutations have long been recognized as the most important prognostic factor in advanced NSCLC patients in the era of EGFR-TKI. Despite the high efficacy of EGFR-TKI, patients harbouring *EGFR* mutations can have extremely short PFS, but means of identifying patients whose tumours do not respond well to these drugs are lacking. In this study, we collated two groups of advanced NSCLC patients harbouring *EGFR* mutations with different PFS spans and found the concurrent driver gene mutations to be more frequent in short PFS group. This finding indicates that the concurrent driver gene mutations might be a negative predictive factor. To the best of our knowledge, this is the first study comparing genetic differences between short and long PFS patients.

The recent wide spread use of NGS enables us a full view of genetic alteration in NSCLC. In several previous studies, concomitant somatic mutation and complex *EGFR* mutation have been reported to be predictive factors related to the PFS of patients treated with first generation TKI \[[@bb0035],[@bb0045],[@bb0095]\]. We profiled the genetic landscape of patients and explored for possible genomic alterations contributing to differences in TKI efficacy.

In our study, the clinical parameters in the two groups were not significantly different. Patients were mainly female and non-smoker, in accordance with previous reports. Mutation of exon 21 was the predominant mutation in both groups, which might because of the highly selection and limited number of patients. The high prevalence of complex *EGFR* mutations and high incidence of de novo T790M were observed in the study due to the selection of short PFS patients and the high sensitivity of the NGS method.

Acquired resistance of T790M was the most common resistance mutation in patients treated with first generation EGFR-TKIs. Additionally, previous studies suggested that the pre-existing T790M could present as a co-occurring mutation in a small population of *EGFR* positive NSCLC patients. The incidence of de novo T790M is 35%--60% in these patients \[[@bb0100],[@bb0105]\]. Pretreatment T790M was reported to be a poor prognostic factor in NSCLC patients \[[@bb0110], [@bb0115], [@bb0120]\]. While using EGFR-TKI mono-therapy, shorter PFS was shown for patients with T790M than without \[[@bb0110]\]. The combined use of EGFR-TKI and bevacizumab might prolong PFS in the T790M-positive subgroup \[[@bb0125]\]. Our study also indicated that patients with short PFS tended to have more T790M mutations, although de novo T790M also existed in long PFS patients. The abundance of T790M was higher in the short PFS group and the T790M rate to EGFR was significantly higher in the short PFS group, which was also consistent with previous studies \[[@bb0130]\]. This may indicate that the abundance of T790M is important in predicting the efficacy of EGFR-TKIs, especially when using highly sensitive detection methods. And combination therapy with bevacizumab might be of choice in these patients \[[@bb0125]\].

Co-occurring driver gene mutations other than *EGFR* were found only in the short PFS group. These patients had *ALK* fusion, *MET* amplification, or *BRAF V600E* mutation aside from EGFR-sensitive mutations. Previous reports indicated that the co-occurring of driver mutations were rare \[[@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155]\] and were associated with resistance to TKI therapy \[[@bb0095],[@bb0160]\]. In the current study, patients with co-occurring driver gene mutations were much more in the short PFS group than in the long PFS group (10% vs. 33%, *P* = 0·018), which suggests the co-occurrences of driver gene mutations might be the most important factor affecting clinical outcomes.

The reported incidence of concomitant ALK rearrangement and EGFR mutation was 1.3% to 1.6% \[[@bb0140],[@bb0155]\]. And the coexistence of *ALK* rearrangement could be predictive of poor response in patients treated with EGFR-TKIs \[[@bb0165],[@bb0170]\]. First line ALK-TKIs therapy might bring out a better outcome in these patients \[[@bb0160],[@bb0175],[@bb0180]\]. *MET* amplification is another known resistant mechanism of EGFR-TKI therapy. The baseline *MET* amplification in *EGFR*-mutant patients seems to be small (3.2%) \[[@bb0185]\]. These patients may response to *MET* inhibitors and crizotinib in previous reports \[[@bb0190], [@bb0195], [@bb0200]\]. Co-mutation of *BRAF V600E* was also rare. The experience of targeted therapy in these patients still needs to be defined. Due to the limited number of patients, all the experiences of treatment were from case reports. Moving forward, identifying the appropriate therapeutic strategy for co-occurring with *ALK*, *MET*, and *BRAF* mutations in *EGFR*-mutant NSCLC will require increasingly nuanced molecular screening strategies and well-designed clinical trials.

Several previous studies have investigated the association of concomitant genetic alterations with response and survival \[[@bb0035], [@bb0040], [@bb0045], [@bb0050]\]. These studies challenged the single driver oncogene view and revealed the potential function of co-occurring genetic alterations as co-drivers of tumor progression \[[@bb0050]\]. In the current study, the percentage of patients with co-occurring resistance mutations were higher in the short PFS group than in the long PFS group (*P* = 0·018). The result is consistent with previous studies and suggests that co-occurring driver gene mutations play an important role in tumor progression and drug resistance and might be a very important factor affecting clinical outcomes.

Co-existence of somatic gene mutations was also analysed. The results indicated that concomitant mutation of *TP53* was the most frequent somatic mutation in advanced NSCLC \[[@bb0160],[@bb0205]\], in line with previous reports \[[@bb0210]\]. The missense mutation of *TP53* was more prevalent in the short PFS group, but the difference between the two groups was not significant.

*RB1* is a tumor suppressor gene, whose mutations occurs in a variety of cancers and emerges as a cause of acquired resistance to EGFR antagonists \[[@bb0215]\]. Niederst et al. had described the association between *RB1* loss and the transformation to SCLC in EGFR-mutant NSCLC \[[@bb0220]\]. Aurora B kinase inhibitor was reported to be efficacious in *RB1* loss SCLC models \[[@bb0215]\]. But the impact of pretreatment *RB1* in NSCLC was unknown. In previous report, the median interval between the initiation of EGFR-TKI to small cell lung cancer (SCLC) transformation was 15·8 months \[[@bb0225]\]. Thus, we speculated that the *RB1* loss might be a relatively indolent mutation. In our study, *RB1* were found in both groups. No different of frequency were seen between the two groups. Specified treatments for these patients need further clinical researches and investigations.

*MAP2K2* amplification was found only in the long PFS group (*P* = 0·036), but we were unable to conclusively demonstrate its positive prognostic value due to the limited number of cases.

We further compared the occurance of concomitant mutations, the number of genes in the EGFR-related pathway and the number of total somatic gene mutations between the two groups, but found no significant differences, in contrast to previous studies \[[@bb0035]\]. This indicated that co-occurring somatic mutations that were not driver mutations were not strong predictive factors for patients treated by EGFR-TKIs.

In addition, our study analysed the differences of concomitant mutation number and TMB in the two groups. The result showed that the short PFS group had more patients whose TMB was higher than eight. However, neither the mean number of mutations nor the TMB level were significantly different between the two groups. There are several possible mechanisms for this. TMBs of patients developing T790M resistance were lower, and TMB was not affected in patients with SCLC transformation after developing TKI resistance \[[@bb0230]\]. This suggests an explicit resistance gene or mechanism serving as a single oncogene and leading to lower heterogeneity of lung cancer. In our study, the incidence of pretreatment-resistant mutations, including T790M, was high in the short PFS group; this may have contributed to the lower mean TMB. However, this hypothesis requires additional further study for confirmation.

There are several limitations in this study. First, since this was a retrospective analysis with all patients at advanced stages of disease, the number of patients and contributing tissue samples were limited. Only approximately 55% of the patients had sufficient DNA extracted for NGS. Second, we included patients receiving different lines of TKI treatment. The last, due to the insufficiency of remaining tissue, PD-L1 immunohistochemistry was not performed. As conflicting data are present in the literature on the prognostic role of TMB and concomitant somatic mutations in EGFR-positive NSCLC \[[@bb0035],[@bb0205]\], additional prospective studies including more patients should be performed.

In conclusion, our study highlights the co-occurring driver gene mutations, which were significantly more frequent in short PFS group, may serve as important negative predictive factors for TKI therapy in patients with *EGFR* 19del or 21L858R mutations. A high T790M ratio to *EGFR* mutation ratio rather than existence of T790M predicted a shorter PFS. Co-occurring genomic alterations as well as EGFR sensitive mutations should be detected prior to treatment to identify subgroups of patients with less favourable outcomes of TKI therapy.
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